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Targeting CD44v6 for fluorescence-
guided surgery in head and neck 
squamous cell carcinoma
Julia Odenthal1,2, Mark Rijpkema3, Desirée Bos3, Esther Wagena2, Huib Croes2, 
Reidar Grenman4, Otto Boerman3, Robert Takes1 & Peter Friedl2,5,6
Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating 
functionally important tissue areas. Achieving complete tumor resection and preserving functionally 
relevant tissue structures depends on precise identification of tumor-free resection margins during 
surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells using a 
fluorescent tracer, may guide surgical excision and identify tumor-positive resection margins. Using 
a literature survey on potential surface molecules followed by immunohistochemical validation, we 
identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the invasion zone of HNSCC 
lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with both a near-infrared fluorescent 
dye (IRDye800CW) and a radioactive label (Indium-111) and dual-modality imaging was applied in a 
locally invasive tumor mouse model. BIWA accurately detected human HNSCC xenografts in mice with 
a tumor uptake of 54 ± 11% ID/g and invasion regions with an accuracy of 94%. When dissected under 
clinical-like conditions, tumor remnants approximately 0.7 mm in diameter consisting of a few thousand 
cells were identified by fluorescence imaging, resulting in reliable dissection of invasive microregions. 
These data indicate that CD44v6 is a suitable target for reliable near-infrared detection and FGS of 
invasive HNSCC lesions in vivo.
Head and neck squamous cell carcinomas (HNSCCs) are invasively growing tumors in a functionally delicate 
and important area with an overall five-year survival rate below 60%1. Surgical treatment of HNSCC aims to 
completely remove both tumor and marginal invasion zones, and tumor-free resection margins represent a criti-
cal prognostic parameter for reducing tumor recurrence and improving overall survival2. In functionally critical 
areas, such as the head and neck region, maximizing surgical margins has to be weighed against loss of functional 
tissue resulting in compromised quality of life post surgery3. Therefore, developments such as intraoperative 
histology and image-guided surgery aim to more accurately delineate the tumor border during surgery, ena-
bling more accurate tumor resection. As complementary strategy fluorescence-guided surgery (FGS) aims to 
intraoperatively detect a fluorescent tracer after selective accumulation in tumor tissue and enables preclinical 
and clinical detection of cancer lesions eventually resulting in improved progression-free survival after surgery4. 
Improved signal detection has been achieved by conjugating fluorophores in the near-infrared (NIR) range of 
650–900 nm with targeting antibody binding extracellular epitopes preferentially expressed on tumor cells, allow-
ing macro- and microscopic detection of even small tumors and tumor subregions5. This resulted in a range of 
cancer-targeting antibodies developed for FGS surgery to validate molecular targets, establish conjugate safety 
and develop sensitive imaging devices6–8. In clinical trials safe tracer administration and subsequent identification 
of cancers in the sub-millimeter resolution have been demonstrated4,9–11. Potential shortcomings of FGS, how-
ever, include inhomogeneous antigen expression and/or tissue distribution of the antibody as well as non-specific 
antibody uptake in peritumor tissue and limited tumor detection due to high background fluorescence4,12.
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First-generation FGS of HNSCC focused on the epidermal growth factor receptor (EGFR), based on its prom-
inent expression in HNSCC and efficient in vivo detection of tumors and metastasis in preclinical studies13–15. 
A fluorescently-labeled anti-EGFR antibody (cetuximab) is clinically well tolerated and efficiently differentiates 
tumor from normal tissue9,10. However, reliable cetuximab-based FGS is hampered by uncertain sensitivity and 
specificity, as a conseqeunce of variable antigen expression in tumors and high binding of cetuximab to normal 
tissues (tumor stroma, liver, skin, a.o.)16. Thus, identifying antigens with a more tumor restricted expression 
remains pertinent to reliably and selectively visualize HNSCC tumor regions.
To reliably detect the invasion zone of HNSCC, we performed a literature survey and tested the presence of a 
range of potential antigens (over-)expressed in HNSCC including c-Met, CD44 variant 6 (CD44v6), E-cadherin, 
epidermal growth factor receptor (EGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) 
and epithelial cell adhesion molecule (EpCAM). We identify CD44v6 as candidate and apply anti-CD44v6 anti-
body BIWA for sensitive detection of the invasion margins in HNSCC in a preclinical mouse model.
Results
CD44v6 expression in invasive HNSCC. To identify surface markers in HNSCC patient material which 
reliably detect the margin of invasion and, hence, might be suitable for FGS, we applied comparative immuno-
histochemistry on human tumor samples. Candidate cell surface proteins, including c-Met, CD44v6, E-cadherin, 
EGFR, EMMPRIN and EpCAM, were identified based by a literature survey focusing on the percentage of posi-
tive tumors, the homogeneity of expression within the same tumor and whether the protein was expressed on the 
epithelium or the tumor stroma (Suppl. Table 1). As further criteria for marker selection, extracellular cell-surface 
localization and expression level and variability in HNSCC were considered. Additionally, the availability of a 
monoclonal antibody with established low toxicity profile and imaging application in clinical trials was taken into 
consideration. Approximately 97% of HNSCCs were positive for CD44v6 followed by EGFR (85%) and lower fre-
quencies for the other markers. CD44v6 was consistently present throughout the tumor with defined membrane 
staining, but reduced expression in keratinized or necrotizing areas in the tumor core (Fig. 1). EGFR and c-Met 
showed a strong expression throughout the tumor similar to CD44v6 (Fig. 1; Suppl. Fig. 1). Likewise, EMMRPIN 
showed reliable expression throughout the lesion albeit with lower intensity (Suppl. Fig. 1), whereas E-cadherin 
and EpCAM expression were less reliable with notable inter-individual variability (Suppl. Fig. 1). Whereas for 
CD44v6 and EMMPRIN the signal was near-exclusively tumor cell specific with only weak background stain-
ing from the desmoplastic stroma and adjacent epithelial structures, particularly epidermis and hair follicles, 
E-cadherin positivity resulted from both tumor-derived and non-transformed epithelial structures (Fig. 1; Suppl. 
Fig. 1). EpCAM, c-Met and EGFR were also expressed by stromal cells resulting in a high peri-tumor back-
ground signal (Fig. 1; Suppl. Fig. 1). The reliable immunohistochemical staining together with published evi-
dence indicated CD44v6 as epitope with abundant expression throughout HNSCC lesions including the invasion 
zone. For application in FGS, CD44v6-targeting antibodies were previously shown to macroscopically identify 
CD44v6 expressing epithelial xenograft tumors in mice, including HNSCC (Suppl. Table 1)17–19, whereas its suit-
ability for identifying the tumor margin and disseminated invasion zones remain untested. We therefore selected 
Figure 1. Expression of CD44v6 and EGFR in primary human HNSCC samples. Tumor (T), normal 
epithelium (E), stroma (S). Dotted lines mark the tumor edge. Representative samples from 7 (CD44v6) or 5 
(EGFR) independent tumors. Scale bars indicate 1000 µm (overview) and 100 µm (zoom).
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anti-CD44v6 antibody BIWA, the humanized form of which demonstrated safe administration in clinical trials 
and reliably visualized HNSCC lesions by nuclear imaging20,21.
Expression of CD44v6 in HNSCC cell lines and invasive xenograft tumors in mice. To estab-
lish an invasive HNSCC mouse model for FGS, a range of HNSCC cell lines were analyzed for expression of 
CD44v6 and growth pattern in vivo. Consistent with reliable CD44v6 expression in human samples, all HNSCC 
cell lines expressed CD44v6 at high and homogeneous levels in contrast to two melanoma cell lines serving as 
negative controls based on previous findings (Suppl. Fig. 2A)22. UT-SCC58 showed a low-to-medium level of cell 
surface expression (50-fold CD44v6/IgG1 signal-to-background ratio; total range between cell lines 30 to 181), 
which we considered as a representative cell model reflecting non-overstated CD44v6 availability for realistic 
in vivo antibody targeting. As xenograft lesions in mice, UT-SCC58 cells grew within 3–4 weeks to macroscop-
ically visible tumors (Fig. 2A,B) and showed invasive growth pattern characteristics of differentiated HNSCC, 
including nest-like dissemination in the interstitial tissue (Fig. 2C1) and invasion along nerve fibers (Fig. 2C2). 
Co-staining of CD44v6 and pan-cytokeratin as epithelial reference marker indicated a relatively uniform expres-
sion of CD44v6 throughout the lesion (Fig. 2D). Sub-region analysis of the tumor core, border and invasive cells 
as well as scoring of CD44v6 intensity at single cell level revealed constant expression in all tumor areas without 
significant variation (Fig. 2E,F; Suppl. Fig. 2B). Thus, UT-SCC58 xenografts recapitulate the invasive growth and 
CD44v6 expression patterns of patient samples and represent a suitable preclinical model for FGS of invasive and 
moderately CD44v6-positive HNSCC tumors.
BIWA detects CD44v6-expressing tumors in vivo. To detect small metastases and assess the biodis-
tribution of fluorescent tracers, a cohort of UT-SCC58 tumor-bearing mice with a lesion volume of 10–42 mm3 
received 111In-DTPA-BIWA-IRDye800CW or 111In-DTPA-IgG1-IRDye800CW isotype-matched control antibody 
intravenously. Antibody uptake by UT-SCC58 tumors using NIR whole-body fluorescence detection reached a 
maximum three days after injection (data not shown), similar to the bioavailability kinetics reported for other 
antibodies and HNSCC tumor models19,23. 111In-DTPA-BIWA-IRDye800CW showed a most prominent sig-
nal originating from the tumor and weaker signal originating from the left cervical lymph node and the liver 
(Fig. 3A). In comparison, fluorescent signals from 111In -DTPA-IgG1-IRDye800CW were detected in the liver 
and weakly in the tumor (Fig. 3A). SPECT/CT images confirmed this biodistribution profile, whereby one mouse 
also showed weak signal enrichment in the left cervical lymph node (Fig. 3B). Biodistribution analysis revealed 
a mean tumor uptake of 54 ± 11% ID/g for 111In-DTPA-BIWA-IRDye800CW compared to 5 ± 2% ID/g for IgG1 
control antibody conjugate (Fig. 3C). Uptake of dual-labeled BIWA in other organs was considerably lower, quan-
tified as total amount (Fig. 3C) and tumor-to-blood ratio (Fig. 3D). Despite yielding a positive signal (Suppl. 
Fig. 3A) the cervical lymph nodes lacked pan-cytokeratin positive tumor nests (Suppl. Fig. 3B,C) and thus were 
considered tumor-free. Most likely, false-positive detection in lymph nodes resulted from uptake of BIWA by 
macrophages via Fc-receptors, as described for other tumor models24. Thus, systemically applied dual-labeled 
BIWA accumulates in CD44v6-expressing tumors with high selectivity.
BIWA detects invasive tumor regions. To determine whether dual-labeled BIWA is able to detect the 
invasive tumor margin, we performed sub-region immunohistochemistry and NIR fluorescence scans after sys-
temic administration of 111In-DTPA-BIWA-IRDye800CW. Both, the tumor core and invasion zones were mac-
roscopically positive for the near-infrared signal, whereas the surrounding stroma showed a low background 
signal (Fig. 4A; Suppl. Fig. 4). Microscopic analysis revealed cell surface localization of BIWA label on tumor 
cells (Fig. 4A, white arrowheads), consistent with antigen-dependent accumulation after in vivo administration. 
Sub-region co-localization analysis of the CD44v6 NIRF signal after in vivo administration and pan-cytokeratin 
immunofluorescence showed that BIWA detected > 85% of the CK-positive tumor cell nests (Fig. 4A, black 
arrowheads; Fig. 4B). Notably, occasional BIWA-negative tumor clusters were frequently located in direct vicin-
ity (below ~ 250 µm distance) of BIWA-positive regions (Fig. 4A, open arrowheads) and thus would co-localize 
when viewed by intraoperative microscopic surgery with a sub-millimeter resolution. Including such co-localized 
events, 94% of the invasion regions were detected by 111In-DTPA-BIWA–IRDye800CW (Fig. 4B). No signal from 
IgG1 control antibody was detected in both tumor cells or the tumor stroma by histological scoring (Suppl. 
Fig. 4). Taken together, systemically applied dual-labeled BIWA detects all tumor regions and > 90% of invasive 
zones.
Preclinical FGS: sensitive detection of tumor cells. FGS experiments were performed using system-
ically applied BIWA-IRDye800CW detected by the intraoperative QMI Spectrum fluorescence imaging system 
(Quest Medical Imaging), to approximate signal intensity and detection of the tumor margin under clinical-like 
conditions. To simulate incomplete tumor resection and estimate the size of minimal remnants of the resection 
margin based on the BIWA-IRDye800CW label, step-wise FGS was performed until a minimal-residual fluo-
rescent signal was left in situ (Fig. 5A). Subsequently, remnants were detected by high-sensitivity NIRF imaging 
followed by high-resolution immunohistochemistry to validate the presence and amount of tumor cells (Fig. 5A). 
Post-operative immunohistochemistry showed that NIR fluorescence-positive regions also stained positively for 
pan-cytokeratin (Fig. 5B), confirming high selectivity of CD44v6 for the detection of tumor cells. The estimated 
residual tumor masses, which could still be detected by BIWA-IRDye800CW in minimal lesions, were 0.7–2 mm 
in size and contained few thousand to hundred thousand cells, based on NIR scans and immunohistochemistry 
of the residual tissue.
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Discussion
We here show that systemically applied BIWA-IRDye800CW provides sensitive detection of HNSCC lesions 
under clinical fluorescence imaging conditions and allows a precise step-wise removal of the tumor margin 
with a detection limit in the submillimeter range. CD44v6 is expressed in HNSCC across all tumor stages, with 
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Figure 2. Invasive HNSCC mouse xenograft model for in vivo detection of CD44v6. (A) Macroscopic detection 
of a representative small and large tumor in the left cheek of two different mice. Arrowhead indicates the 
tumor location. (B) Growth curve of UT-SCC58 tumors. Data show the means of 12 mice. (C) Central section 
of an UT-SCC58 tumor, showing multifocal invasive tumor islands in the interstitium (1) and in perineural 
location (2). Scale bars indicate 500 µm (overviews) and 100 µm (zooms). (D) Expression of CD44v6 and 
pan-cytokeratin (CK) in UT-SCC58 tumors. Dotted lines mark the tumor border and tumor islands. Scale 
bars indicate 500 µm (overviews) and 100 µm (zooms). (E) Whole-region analysis of (D). Staining intensity 
of CD44v6 in different areas analyzed at day 28 after implantation. Data show medians from 12–38 analyzed 
images per tumor from 4 independent tumors. (F) Single cell analysis of (D). Fluorescence intensities  
after background substraction for CD44v6 and CK of the same tumors as in (E). 50 cells were analyzed per 
subregion and geometric symbols represent 5 different tumors. Core of the tumor (C), border of the tumor (B), 
distant cells (DC), skin (S).
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varying trends in T stage and/or nodal status25–28. The robust expression of CD44v6 across independent HNSCC 
lesions and most, if not all, HNSCC tumor cells and the availability of clinically applicable anti-CD44v6 antibody 
Bivatuzumab emphasize CD44v6 as promising antigen for reliable FGS in HNSCC cancer, enabling visualization 
of tumor margins and minimal residual lesions. Besides in primary tumors, CD44v6 is expressed in recurrent 
tumors and lymph node metastases27,29,30, therefore administration of 111In or IRDye800CW labeled Bivatuzumab 
should enhance detection of primary as well as secondary and metastatic HNSCC disease. When directly com-
pared, CD44v6 expression is approximately 8-fold higher in HNSCC samples compared to EGFR31. CD44v6 is 
expressed only in a subset of adjacent normal epithelia and absent or only weakly expressed in other, non-tumor 
tissues30, which minimizes background signal, systemic uptake and potential off-target effects. In addition, radi-
olabeled Bivatuzumab, which targets the same epitope as BIWA, was successfully applied for scintigraphic in vivo 
imaging of HNSCC tumors in mouse models and patients with low toxicity and immunogenicity19,32,33. Tumor 
uptake of the dual-labeled BIWA in UT-SCC58 tumors with moderate CD44v6 expression was comparable to 
that of radiolabeled anti-CD44v6 antibodies, while tumor-to-blood ratios even exceeded previously reported 
results17,19.
Using detailed immunohistochemical analysis of CD44v6 in patient material and by in vivo targeting of 
HNSCC xenografts by BIWA, we demonstrate that CD44v6 is strongly expressed in the invasion margin of tumor 
lesions and thus suitable for precise microscopic FGS mapping of invasive HNSCC. Using minimal lesion anal-
ysis, we identify high detection sensitivity of BIWA-IRDye800CW using a clinical fluorescence imaging system 
detecting as little as sub-millimeter sized residues containing only a few thousand cells. The staining pattern was 
predominantly cell-surface associated with heterogeneous targeting in the main tumor mass, potentially caused 
by heterogeneous antibody distribution34. However, the consistent labelling of tumor borders and invasive cells 
indicated that Bivatuzumab may enable reliable intraoperative fluorescent imaging of both, invasion zone and 
small tumor remnants.
Besides HNSCC, CD44v6 is expressed in most carcinoma types, including lung, skin, cervix, breast and 
colon30. Thus, beyond HNSCC, CD44v6 may serve for probing resection margins in a range of other inva-
sive tumor types. CD44v6 targeting antibodies have achieved reliable NIR fluorescence enrichment in vivo in 
breast cancer xenografts18 and immuno-PET imaging in a thyroid carcinoma model35. Likewise, 186Re-labeled 
Bivatuzumab was safely administered to patients with early-stage breast cancer, but failed to reliably detect small 
Figure 3. Biodistribution of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW control 
antibody in mice carrying HNSCC tumors in the left cheek for 28 days and 72 h after i.v. administration. (A,B) 
Near infrared fluorescent (NIRF) whole body images of mice n = 9 (A) and corresponding micro SPECT/CT 
images n = 4 (B). Tumor (T), lymph node (LN), liver (L). (C) Biodistribution data shown as percentage injected 
dose per gram of tissue of both dual-labeled antibodies. (D) Tumor-to-blood ratios obtained by ratios from (C).
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lesions with low CD44v6 expression36. Thus, further studies will be required to establish the application in small 
lesions with clinically variable CD44v6 expression.
Besides application as a single agent, CD44v6 detection may be combined with EGFR detection, the expres-
sion of which, in contrast to CD44v6, increases in poorly differentiated carcinomas16,30. Thus, combining CD44v6 
Figure 4. Detection of invasive tumor regions by dual-labeled BIWA 3 days after systemic administration. (A) 
Central, serial sections of a tumor (H&E staining, CK staining and NIRF signal). Images show invasive tumor 
islands (1, 2, dotted line) adjacent to the main tumor (3, dotted line). Tumor (T), normal epithelium (E), stroma 
(S). Black arrowheads indicate fluorescent positive islands, the transparent arrowhead a negative/weakly stained 
island. White arrowheads highlight membranous staining. Scale bars indicate 1 mm (overview) and 100 µm 
(zoom). (B) Scoring of NIRF signal intensity for tumor core, border and invasive cells including isolated nests 
and clusters of adjacent islands. Data represent scoring of two sections per tumor in 5 mice. *Example shown in 
Suppl. Fig. 4, **Example shown in Fig. 4A.
www.nature.com/scientificreports/
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and EGFR targeting may increase overall sensitivity for the detection of poorly differentiated carcinomas. 
Additional epitopes for dual- or multi-targeted FGS may include c-Met and EMMPRIN, based on high expression 
in HNSCC samples and their presence in the invasive front (Suppl. Table 1). In conclusion, based on its beneficial 
signal-to-noise ratio and low side effects32 Bivatuzumab, as either NIR-fluorescence- or dual-labeled conjugate, 
shows potential to improve the outcomes of surgical treatment in HNSCC.
Figure 5. Preclinical FGS using BIWA-IRDye800CW and post-resection validation. (A) Experimental 
procedure of step-wise tumor resection, in situ detection and post-fixation analysis. (B) (1) UT-SCC58 tumors 
28 days after implantation into mice were monitored by intraoperative fluorescence imaging (QMI Spectrum) 
followed by step-wise FGS. Dotted lines mark the mouse and tumor tissue and the arrow indicates weak 
fluorescent signal from tumor remnant in situ. Numbers show tumor-to-background ratios. (2) Post-operative 
high-sensitivity NIR fluorescence analysis of excised tissues and in situ remnant using the Odyssey CLx flatbed 
scanner. The scale bar indicates 1 mm. Further processing and re-scanning of the tumor remnant as 400- and 
then 7-µm thick sections. Immunofluorescence of a NIRF-positive 7 µm section of the remnant. Scale bars 
indicate 500 µm (overview) and 100 µm (zoom). The total estimated remnant tumor cells and size are shown for 
four experiments.
www.nature.com/scientificreports/
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Material and Methods
Literature survey. A systematic PubMed search was performed to identify potential cell surface markers 
expressed in the invasion region of HNSCC. The following search strategies were used for a publication period 
from 1985 to September 2015: protein name + immunohistochemistry + head and neck squamous cell carci-
noma; protein name + imaging + head and neck squamous cell carcinoma. As indicator, the percentage of 
patients positive for the protein of interest was averaged from retrieved articles and, where available, differential 
expression within different tumor regions was taken into account (tumor core, tumor border, surrounding tumor 
stroma).
Immunohistochemistry of patient material. Tissue samples from 7 HNSCC patients were obtained 
from the Department of Pathology, Radboudumc, Nijmegen. Tumor samples were encrypted and analyzed in an 
anonymized manner, as approved by the institutional review board and according to national law. Formalin-fixed 
and paraffin-embedded tissues were cut into sections of 4 µm thickness, mounted onto SuperFrost slides (Thermo 
Scientific) and dried overnight at 37 °C. Sections were deparaffinized in xylene, rehydrated in graded alcohols to 
water, quenched of endogenous peroxidases (0.3% H2O2, 30 min), boiled in citrate buffer for antigen retrieval (pH 
6, 13 min), pre-incubated with normal goat serum (20%, 30 min), washed and incubated with primary antibody 
(4 °C, overnight). The following antibodies were used: monoclonal mouse anti-human E-cadherin (SPM471, 
1/300; Thermo Scientific), monoclonal mouse anti-human EpCAM (VU1D9, 1/200; Thermo Scientific), mono-
clonal rabbit anti-human c-Met (EP1454Y, 1/200; Epitomics), polyclonal rabbit anti-human EGFR (sc-03, 1/200; 
Santa Cruz); monoclonal mouse anti-human EMMPRIN (sc-21746, 1/200; Santa Cruz) and monoclonal mouse 
anti-human CD44v6 (VFF-18, 1/1000; AbD Serotec). After washing, sections were incubated with biotinylated 
secondary goat anti-mouse or anti-rabbit antibody and subsequently with the VECTASTAIN ABC reagent 
(Vector Laboratories) according to the manufacturer’s protocol. The signal was developed with diaminobenzi-
dine and counterstained with hematoxylin. Sections were dehydrated in ethanol and xylene and mounted with 
Pertex (Histolab). Negative controls (buffer only) were included in each analysis. Sections were imaged with an 
automated slide scanner with a 20x, 0.243 µm/pixels objective (Pannoramic 250 Flash II, 3DHITECH).
Cell culture. HNSCC cell lines from primary human SCCs of cutaneous SCC (UT-SCC12A), tongue 
(UT-SCC16A and UT-SCC40), glottic larynx (UT-SCC38), supraglottic larynx (UT-SCC42B) as well as from 
metastases of SCCs of cutaneous SCC (UT-SCC12B), tongue (UT-SCC16B) and transglottic larynx (UT-SCC58) 
were established at the University of Turku, Finland37. Other cells used were FaDu cells (kind gift by the Dept. of 
Radiation Oncology, University of Technology Dresden) and the human melanoma cell lines A3755M (kind gift 
from Dr. Menashe Bar-Eli/Dr. Michael Davis, MD Anderson Cancer Center, USA) and MV338. All cells were cul-
tured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen), supplemented with 10% heat-inactivated fetal 
calf serum (Sigma Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin (both PAA), 2 mM L-glutamine, 
1 mM sodium pyruvate (both Invitrogen/Life technologies) and 20 mM HEPES (Gibco).
Flow cytometry. 2 × 105 HNSCC and melanoma cells were seeded in 6-well plates two days prior to the 
experiment. Cells were detached with 4 mM ethylenediamine tetraacetic acid (EDTA) and stained on ice with 
murine anti-human CD44v6 antibody (BIWA), the humanized form of which has been applied clinically (biva-
tuzumab; BIWA-4)19,39 or a human IgG1 istotypic control (Alpha Diagnostic Intl. Inc.) and a secondary goat 
anti-mouse/human 647 antibody (ThermoFisher Scientific). CD44v6 expression and cell viability co-registered 
by lack of propidium iodide uptake were obtained by flow cytometry (FACS Caliber) and analyzed using the FCS 
Express software (version 5).
Mouse model. The animal experiments were performed in accordance with the guidelines and rules of 
the Dutch Act on animal experiments (WOD) and was approved by the Animal Welfare body of the Radboud 
University, Nijmegen (RU-DEC 2014-142). 9 × 105 UT-SCC58 cells suspended in 3 mg/ml Matrigel (total vol-
ume 50 µl; BD Biosciences) were injected into the floor of the mouth of BALB/c nu/nu female mice (6–8 weeks 
old; Charles River Laboratories). Tumors were allowed to grow for 4–6 weeks. Tumor growth over time was 
measured using a caliper.
Antibody conjugation. Antibodies were used as either fluorescence-only or dual-labeled conjugates car-
rying fluorescence and the radioactive isotope 111In. Human IgG1 isotypic control antibody (Alpha Diagnostic 
Intl. Inc.) was dialyzed against phosphate buffered saline (PBS) using the 10,000 Da molecular weight cutoff 
Slide-A-Lyzer MINI Dialysis device (Thermo Scientific) to remove azide and other additives. To generate NIR 
fluorescent conjugates, BIWA (1 mg) was incubated with a 3-fold excess of IRDye800CW-N-hydroxysuccinamide 
(NHS) in 0.1 M sodium carbonate buffer (pH 8.5) for 1 h at room temperature (RT). For fluorescence guided sur-
gery experiments, BIWA was only labeled with IRDye800CW-NHS. The final concentration of the antibody and 
the molecular substitution ratio were determined spectrophotometrically (Ultrospec 2000 spectrophotometer, 
Pharmacia Biotech) yielding an antibody:fluorophore ratio of 1:2. BIWA-IRDye800CW was stored in the dark 
at 4 °C.
For dual-labeling, IRDye800CW-labeled antibodies were conjugated with the chelator p-isothiocyanatobenzyl- 
diethylenetriaminepentaacetic acid (ITC-DTPA) with a 10-fold excess in 0.1 M sodium carbonate buffer (pH 
9.5) for 1 h at RT. The solution was dialyzed for 1 week against 0.25 M ammonium acetate (pH 5.5) using a 
Slide-A-Lyzer cassette with a molecular weight cutoff of 20,000 Da (Thermo Scientific). The final concentration of 
the antibody and the molecular substitution ratio of the fluorescent dye were determined spectrophotometrically 
(Ultrospec 2000 spectrophotometer, Pharmacia Biotech) yielding a ratio of 1.4. DTPA-BIWA-IRDye800CW and 
DTPA-IgG1-IRDye800CW were stored in the dark at 4 °C until further use.
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For radiolabeling, DTPA-BIWA-IRDye800CW and DTPA-IgG1-IRDye800CW were incubated with 0.05 MBq 
of 111In (Mallinckrodt) per microgram of antibody in two volumes of 0.5 M 2-(N-morpholino)ethansulfonic acid 
(MES) buffer (pH 5.5). For SPECT/CT studies antibodies were labeled with 1.5 MBq of 111In per microgram of 
antibody. After incubation of 20 min at RT 50 mM EDTA was added to a final concentration of 5 mM to che-
late unincorporated 111In. Labeling efficiency was determined by instant thin-layer chromatography on silica gel 
strips (Agilent Technologies) using 0.15 M citrate buffer, pH 6.0 as the mobile phase. For all preparations, the 
radiochemical purity of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW exceeded 95%.
Unperturbed immunoreactivity of the antibody conjugates was confirmed as described40 with minor modifi-
cations. A serial dilution of UT-SCC58 cells was incubated with radiolabeled antibody conjugate (333 Bq equiva-
lent to 6.7 ng antibody per dilution in DMEM medium) for 30 min at 37 °C. To determine nonspecific binding, an 
excess of unlabeled antibody conjugate was added to a duplicate of the lowest cell concentration. Unbound anti-
body was removed by washing with DMEM and samples were analyzed in a γ-counter (Wizard; Pharmacia-LKB). 
For all preparations, the immunoreactive fraction of available antibody exceeded 85%.
SPECT/CT and fluorescence whole body imaging. Mice bearing UT-SCC58 tumors in the left cheek 
were injected into the tail vein with either 10 µg of the dual-labeled antibody 111In-DTPA-BIWA-IRDye800CW or 
111In-DTPA-IgG1-IRDye800CW. Three days after injection the distribution of the tracer was determined with a 
U-SPECT II SPECT/CT scanner (MILabs, Utrecht, The Netherlands) in four mice using a 1.0-mm-diameter mul-
tipinhole mouse/rat collimator (2 × 25 min with 44 bed positions). Images were reconstructed by ordered-subset 
maximization expectation using the MILabs reconstruction software (U-SPECT-Rec, Milabs, Utrecht, The 
Netherlands) with the following settings: selection of the lower 111In photopeak (152–183 keV), corrected for two 
backgrounds (135–151 keV and 184–211 keV), pixel based OSEM, voxel size 0.4 mm3 and 1 iteration over 16 sub-
sets. After SPECT imaging, all mice were euthanized and whole-body fluorescence images were acquired (IVIS 
Lumina imaging system, Caliper Life Science) using the following settings: F/Stop - 2, excitation filter - 745 nm, 
emission filter - ICG, field of view - C, 675 nm autofluorescence and background correction, recording time of 
1 min and medium binning factor. Images were processed with the IVIS Lumina software.
Biodistribution analysis. Three days after intravenous administration of the antibodies and whole-body 
imaging, the biodistribution of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW in body 
fluids and excised organs of mice were determined. Blood was collected by heart puncture and tissue samples of 
the tumor lesion, superficial cervical lymph nodes, muscle, heart, lung, spleen, pancreas, kidney, liver, stomach 
and duodenum were collected, weighed and the radioactivity was measured in a well type γ counter (Wallac 2480 
wizard, Perkin Elmer). Radioactivity uptake in each tissue was calculated as the percentage of the injected dose 
per gram of tissue.
Immunohistochemistry of mouse tumors and cervical lymph nodes. Frozen tumor sections 
(7 µm thickness) were fixed in ice-cold methanol (10 min), washed and pre-incubated with normal goat serum 
(5%, in 1% BSA, 1 h) followed by incubation with primary antibody (overnight, 4 °C). Formalin-fixed cervical 
lymph nodes and tumors were embedded in paraffin, sectioned (7 µm), mounted onto SuperFrost slides (Thermo 
Scientific), dried overnight (37 °C), deparaffinized in xylene and rehydrated in graded alcohols to water. Sections 
were stained with hematoxylin eosin (H&E) or boiled in EDTA/Tris buffer (pH 9, 15 min) for antigen retrieval 
and pre-incubated with normal goat serum (5%, in 1% BSA, 1 h) followed by incubation with antibody (over-
night, 4 °C). The following antibodies were used: polyclonal rabbit anti-human and mouse pan-cytokeratin 
(CK) (ab9377, 1/100; Abcam); monoclonal murine anti-human CD44v6 (BIWA, 5 µg/ml; kind gift from V. 
Orian-Rousseau, Karlsruhe Institute of Technology, Germany). After washing, sections were incubated with sec-
ondary goat anti-rabbit Alexa Fluor 546 and goat anti-mouse/human Alexa Fluor 647 antibody (Invitrogen) for 
2 h at RT and counter stained with DAPI (Sigma). Negative controls were obtained by IgG isotype staining and 
tumor tissue served as positive controls for lymph node staining. Fluorescence on tissue sections was imaged 
using a 10x NA 0.25 objective (DMI6000B slide scanner, Leica) and H&E staining using a 20x 0.243 µm/pixels 
objective (Pannoramic 250 Flash scanner, 3DHITECH).
Digital image analysis was performed using Fiji (software version 1.51k, https://imagej.net/Fiji). Fluorescence 
intensity of CD44v6 and CK were co-registered for tissue subregions from images containing skin, local invasion, 
the core or the border of the tumor and each subregion was manually segmented based on topology, DAPI and 
CK signal. Mean CD44v6 and CK fluorescence intensities in individual cells were obtained using same region of 
interest, using an area of 51 µm2 to sufficiently represent the size of single cells. Fluorescence intensities were nor-
malized by subtracting the mean intensity from five background measurements from tumor-free tissue regions.
NIR imaging and analysis of mouse tumors and lymph nodes. Fresh-frozen tumor tissue from mice 
after i.v. administration of 111In-DTPA-BIWA-IRDye800CW or 111In-DTPA-IgG1-IRDye800CW were sectioned 
(7 µm thickness) and two positions with at least 400 µm distance were scanned for NIR fluorescence intensity (set-
tings: slide, intensity 2, resolution 21 µm, highest quality; Odyssey CLx, LI-COR Biosciences). Regions of interest 
identified by fluorescence detection from the Odyssey scans were re-sampled with high resolution by NIR imag-
ing (20x NA 0.8; mono setting, 5 sec acquisition time; Nuance-XR, PerkinElmer). Further subsampling and val-
idation of fluorescence-positive regions obtained by Odyssey scanning were obtained by H&E and CK staining.
Fluorescence-guided surgery. UT-SCC58 tumor-bearing mice after 28 days of growth in the left cheek 
received 10 µg of BIWA-IRDye800CW by tail vein injection. Three days later whole-body fluorescence was 
detected under isoflurane anesthesia followed by euthanasia. For intraoperative fluorescence detection, the 
tumor-containing cheek including surrounding fluorescence-negative tissue was surgically isolated and moni-
tored in real-time using the Spectrum camera system (Quest medical imaging, Wieringerwerf) under clinically 
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used imaging conditions. To match step-wise tumor resection conditions, sequential removal of the lesion guided 
by fluorescence was performed, until a weak but nonetheless positive signal in situ was obtained, reflecting a mini-
mal tumor residue. Tumor-to-background signals were analyzed using Fiji (software version 1.51k, https://imagej.
net/Fiji). For verification of fluorescence, all freshly excised tissue samples including the residual lesion in the 
cheek in situ were subjected to high-sensitivity NIR scanning (instrument settings as described above; Odyssey 
CLx, LI-COR Biosciences) as native whole-mounts, followed by fixation (10% formalin, over night, RT, in the 
dark). Images were used to estimate the remnant tumor size. To detect both antibody distribution and topology 
of the resected lesions, the cheeks were sliced into 400 µm thick sections (Vibratome VT 1000 S, Leica), scanned 
again for fluorescence (Odyssey CLx), embedded in paraffin, sliced into 7 µm thick sections and scanned for NIR 
fluorescence (Odyssey). Subsequently, samples were stained for CK and DAPI or H&E and the amount of tumor 
cells in the remnant was estimated by counting the tumor cells of one central slide multiplied by the volume of 
cytokeratin positive sections, taking into account that each nucleus is present on every 1.7 section based on a 
mean diameter of a tumor cell nucleus of 12.3 µm (averaged from 50 UT-SCC58 cell nuclei).
Statistics. Statistical analysis was performed using the non-parametric Mann-Whitney test with a post-hoc 
correction for multiple comparisons (p ≤ 0.05/N).
Data Availability. Datasets generated during and/or analyzed during the current study are available from the 
corresponding author on reasonable request.
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